Oxalate Reduction by Oral Administration of Oxalate Degrading Enzymes

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$150,788.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK089720-01
Agency Tracking Number:
DK089720
Solicitation Year:
2010
Solicitation Topic Code:
NIDDK
Solicitation Number:
PHS2010-2
Small Business Information
CAPTOZYME, LLC
CAPTOZYME, LLC, 5745 SW 75TH ST, STE 298, GAINESVILLE, FL, 32608
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
831048504
Principal Investigator:
QINGSHAN LI
() -
Business Contact:
COWLEY
(785) 760-3128
aaron.cowley@captozyme.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Severe diseases or conditions such as primary hyperoxaluria (PH), secondary hyperoxaluria (SH), and Zellweger spectrum disorders (ZSD) continues to be a healthcare problem. These diseases occur when oxalate is readily absorbed from dietary sources or from liver overproduction. Oxalate absorption and secretion occur throughout the entire gastrointestinal (GI) tract, but net flow reflects absorption. High concentrations of oxalate and deposition of calcium oxalate (CaOx) crystals in the kidneys can evoke an inflammatory response and induce tubulointerstitial damage leading to fibrosis, loss of nephrons, and eventually to chronic and end-stage renal failure. CaOx supersaturation in blood can result in CaOx crystal deposition in multiple organs, which can cause organ dysfunction or transplanted organ failure. There is currently no effective treatment for such conditions. Therefore, the approach underlying this application is to reduce urinary and plasma oxalate by limiting dietary absorption and by increasing the oxalate secretion rate from the blood to the GI tract where soluble metabolically derived oxalate can be continuously removed by two highly active purified oxalate-degrading enzymes that are capable of removing oxalate throughout the vast GI tract. PUBLIC HEALTH RELEVANCE: Severe disease conditions, such as primary hyperoxaluria, secondary hyperoxaluria, and Zellweger sprectrum disorders, which are the result of increased dietary absorption or metabolic synthesis of oxalate continues to be a healthcare problem. Since there is currently no effective treatment at degrading oxalate throughout the entire GI tract, Captozyme is proposing to develop a combination of oxalate-degrading enzymes that can effectively intercept dietary oxalate as well as remove metabolically generated oxalate throughout the vast GI tract.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government